NWBO
Northwest Biotherapeutics, Inc.·Healthcare
0.21
0.478%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.1952W H: $0.37
NWBO NEWS
prnewswire.com
Apr 30
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
BETHESDA, Md., April 30, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the appointment of Annalisa Jenkins, M.B.B.S.
prnewswire.com
Apr 21
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
BETHESDA, Md., April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it is establishing its own dedicated clinic for leukapheresis procedures at The London Welbeck Hospital.
defenseworld.net
Apr 1
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?
Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $0.25 and traded as low as $0.1950. Northwest Biotherapeutics shares last traded at $0.2065, with a volume of 2,140,465 shares. Northwest Biotherapeutics Price Performance The company's
